Skip to content

ICG-based Fluorescence Imaging in Localization of Prostate Cancer and Metastatic Lymph Nodes

A Pilot and Feasibility Study of Indocyanine Green-based Fluorescence Imaging in Localization of Prostate Cancer and Metastatic Lymph Nodes

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02840617
Enrollment
50
Registered
2016-07-21
Start date
2016-03-31
Completion date
Unknown
Last updated
2016-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

ICG, prostate cancer

Brief summary

This study aims to evaluate the feasibility of indocyanine green (ICG)-based fluorescence imaging in the detection of prostate tumors and metastatic lymph nodes. By correlating the ICG fluorescence patterns with pathologically confirmed tumor and nodal status, it would be possible to use fluorescence navigation system in helping prostate biopsy and lymph node dissection in the future.

Detailed description

The investigators will conduct an in vivo and in vitro pilot study in order to evaluate the diagnostic performance of fluorescence in the detection of prostate cancer and metastatic lymph nodes. All the patients included in this study will receive a radical prostatectomy after intravenous injection of 0.4 mg/Kg of ICG. ICG will be administered immediately after the patient is anesthetized. The fluorescence analysis will be performed intraoperatively by laparoscopic imaging and after surgery by hand-held imaging. The prostate or lymph nodes specimen with or without fluorescence signal will be sent to the Department of Pathology for pathological analysis. The histopathological procedure will be performed without knowledge of fluorescence analysis.

Interventions

DRUGIndocyanine Green (ICG)

Sponsors

Third Affiliated Hospital, Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed prostate cancer; * Able to accept total prostatectomy; * Patient has given its informed consent.

Exclusion criteria

* Allergic to ICG or iodine; * High-grade hepatic insufficiency * refuse attending the study

Design outcomes

Primary

MeasureTime frameDescription
sensitivity and specificity of the ICG-based fluorescence to detect prostate cancer1 week post-surgerysensitivity (true positive) and specificity (true negative) of the ICG-based fluorescence to detect prostate cancer in vivo and in vitro compared to histological analysis

Secondary

MeasureTime frameDescription
sensitivity and specificity of the ICG-based fluorescence imaging to detect metastatic lymph nodes1 week post-surgerysensitivity (true positive) and specificity (true negative) of the ICG-based fluorescence to detect metastatic lymph nodes in vivo and in vitro compared to histological analysis

Countries

China

Contacts

Primary ContactRongqin Zheng RQ Zheng, doctor
zhengrq@mail.sysu.edu.cn0086-02085252010
Backup ContactHuichao Zhou HC Zhou, doctor
zhcgrace@163.com0086-02085252010

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026